Evaluation of Knowledge on Tick-borne Encephalitis Virus (TBEV) Infection Among General Practitioners in France
NCT07191223 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2025-09-24
Summary
Tick-borne encephalitis is a relatively rare disease (approximately 35 cases diagnosed per year), but most cases (86%) are due to contamination in France via a tick bite. Of the 71 cases reported over two years (May 2021 to May 2023), 94% of patients were hospitalized.
It is therefore important to consider and diagnose at the first signs to ensure appropriate follow-up and also to implement primary prevention in endemic/at-risk areas.
Conditions
- Tick-borne Encephalitis, France
Sponsors & Collaborators
-
University Hospital, Strasbourg, France
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-02-16
- Primary Completion
- 2026-02-16
- Completion
- 2026-02-16
Countries
- France
Study Locations
More Related Trials
-
New Study - Humoral Response to Tick-borne Encephalitis Vaccine in Elderly
NCT02318069 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Seroprevalence of Neutralizing Antibodies Against Japanese Encephalitis Virus Among 6 Years Old Children With 5 Different Immunization Strategies in Zhejiang Province
NCT04817917 ·Status: UNKNOWN ·Phase: PHASE4
-
Evaluation of Long-Term Immunogenicity in Subjects Boosted With a TBE Vaccine for Adults
NCT00311493 ·Status: COMPLETED ·Phase: PHASE4
-
Humoral Response to Tick-borne Encephalitis Vaccine in Elderly
NCT01361776 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
The Aim of This Study is to Investigate the Persistence of Antibody Response in Adults up to 15 Years After One Booster Dose of GlaxoSmithKline (GSK) Biologicals' Encepur Adults Vaccine
NCT03294135 ·Status: COMPLETED ·Phase: PHASE4
-
Study of the Safety, Tolerability and Immune Response of TBE Vaccines Administered to Healthy Children
NCT00311441 ·Status: COMPLETED ·Phase: PHASE4
-
Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children
NCT01954810 ·Status: UNKNOWN ·Phase: PHASE4
-
Monitoring JE Antibody Levels in Healthy Populations and Immunization Strategy in Low-Prevalence Areas
NCT06678373 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Immunogenicity and Safety of Inactivated Vero Cell Derived Japanese Encephalitis Vaccine in Thai Children
NCT01408537 ·Status: COMPLETED ·Phase: PHASE3
-
Burden of Invasive Group B Streptococcal (GBS) Disease in Young Infants in China
NCT01933646 ·Status: COMPLETED
-
Vaccine Study for Tick-Borne Encephalitis Virus (TBEV)
NCT01031537 ·Status: TERMINATED ·Phase: PHASE2
-
Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Toddlers
NCT01001988 ·Status: COMPLETED ·Phase: PHASE3
-
Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea
NCT01900444 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling
NCT00776230 ·Status: COMPLETED ·Phase: PHASE3
-
The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers
NCT00718666 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Long-term Evaluation (up to 5 Years) of First Booster Immunization With Novartis' TBE Vaccine for Adults in Adolescents and Adults
NCT00387634 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of a Tdap-IPV (Tetanus, Diphteria, Pertussis and Inactivated Polio) Vaccination Remedial Strategy on Vaccination Coverage in Patients 65 Years of Age or Older
NCT03587610 ·Status: UNKNOWN ·Phase: NA
-
Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX
NCT02526550 ·Status: COMPLETED ·Phase: PHASE4
-
Determining Long-Term Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine
NCT00412516 ·Status: COMPLETED ·Phase: PHASE3
-
Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers
NCT01396512 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity, Safety, and Antibody Persistence of Different Immunization Strategies Against Japanese Encephalitis
NCT06825312 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study
NCT01983553 ·Status: COMPLETED
-
A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers
NCT01092507 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children
NCT00840801 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules
NCT01562444 ·Status: COMPLETED ·Phase: PHASE4